PerioChip®

A biodegradable periodontal chip releasing 2.5mg Chlorhexidine Gluconate over a period of 10 days

Novel OTC formulation

Novel Formulation of a well-known US OTC Brand

Omeprazole DR Tablets

Proprietary Delayed Release Tablet Formulation of Omeprazole OTC

Complex Injectable
(Co-development)

Complex injectable product equivalent to a well-known brand in the oncology field; Co-developed with CSPC Pharma

ViePax® XR
(Venlafaxine XR tablets)

Proprietary Extended Release Tablet formulation bioequivalent to capsule Effexor XR capsules

R&D

Dexcel Pharma is focused on the

development of novel drug formulations

of known molecules and high complexity

generic formulations

 

Strategy

Dexcel Pharma utilizes in-house formulation know-how and proprietary patented oral drug delivery technologies to develop high value branded and generic products.

The company leverages its regulatory expertise to enable new product development and identify niche product opportunities. Our broad industry experience allows us to foster global partnerships for development of new formulations technologies in various delivery methods.

Dexcel Pharma is advancing a carefully selected pipeline of new product developments which continues to expand over time.

Pipeline

Dexcel Pharma’s development pipeline includes more than 30 novel 505(b)2 formulations and complex generics, targeting US and EU markets

Product
Therapeutic area
Development Stage
Preclinical / Formulation
Clinical Development
Registration
Expected Launch
Undisclosed
OTC
2017
Undisclosed
OTC
2017
PerioChip®
(New indication)
Dental
2018
Undisclosed
CNS
2018
Undisclosed
Oncology
2018
Undisclosed
Ophthalmology
2020
Drug Delivery Technologies

Dexcel’s innovative culture has proven successful. Our company invented a number of patent-protected core drug delivery technologies. These include:


  • Fast Dissolving Micro-Based Tablets

    Unique compressible multi-unit system designed for rapid dissolving in the oral cavity with a delayed-release profile.

     

  • Zero Neutralized Delayed Release (ZNDR)

    Reversible neutralized enteric coating used on GI therapeutic areas, such as Dexcel’s proprietary formulation of Omeprazole Delayed Release Tablet

     

  • Periodontal Pocket Delivery System

    The technology utilized PerioChip® for the local release of an antiseptic agent using a unique biodegradable matrix

  • Preconcentrate Technology (PT)

    Soft gelatin capsules filled with liquid containing insoluble drugs. Used for Deximune® (Cyclosporine)

  • Coated Extended Release Technology

    Extended-release tablet-coating formulation, comprising specific mixture of polymers surrounding controlled-release core. Used in ViePax® XR (Venlafaxine extended-release tablet)

  • Biodegradable Polymers

    A line of products for the treatment of various infections at target locations based on biodegradable polymers for improved efficacy and safety over injectable

Collaborations

We are seeking new opportunities for in-licensing novel developments, collaborating on new drug delivery technologies, entering into new commercial agreements in core markets, out licensing branded and generic products and in house development. Contact us